STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells
- PMID: 28849140
- DOI: 10.3892/or.2017.5902
STAT3 inhibition by WP1066 suppresses the growth and invasiveness of bladder cancer cells
Abstract
Signal transducer and activator of transcription 3 (STAT3) regulates the expression of genes mediating cell survival, proliferation and angiogenesis and is aberrantly activated in various types of malignancies, including bladder cancer. We examined whether it could be a novel therapeutic target for bladder cancer using the STAT3 inhibitor WP1066. In T24 and UMUC-3 bladder cancer cells, 5 µM WP1066 prevented the phosphorylation of STAT3 and 2.5 µM WP1066 decreased cell survival and proliferation significantly (P<0.01). WP1066 also induced apoptosis accompanied by the suppression of the expression of Bcl-2 and Bcl-xL in T24 cells. Moreover, the covered area in a wound and the number of cells invading through a Matrigel chamber decreased significantly (P<0.01) when cells were treated with WP1066. The activities of MMP-2 and MMP-9 were also decreased by treatment with 10 µM WP1066. Our results revealed that using WP1066 to inhibit the STAT3 signaling pathway suppressed the viability and invasiveness of bladder cancer cells effectively and could be a novel therapeutic strategy against bladder cancer.
Similar articles
-
STAT3 inhibitor WP1066 as a novel therapeutic agent for renal cell carcinoma.Br J Cancer. 2010 May 25;102(11):1592-9. doi: 10.1038/sj.bjc.6605691. Epub 2010 May 11. Br J Cancer. 2010. PMID: 20461084 Free PMC article.
-
Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.Genet Mol Res. 2015 Mar 30;14(1):2450-60. doi: 10.4238/2015.March.30.3. Genet Mol Res. 2015. PMID: 25867391
-
A novel inhibitor of the STAT3 pathway induces apoptosis in malignant glioma cells both in vitro and in vivo.Oncogene. 2007 Apr 12;26(17):2435-44. doi: 10.1038/sj.onc.1210031. Epub 2006 Oct 16. Oncogene. 2007. PMID: 17043651
-
Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.Int J Oncol. 2018 Jul;53(1):339-348. doi: 10.3892/ijo.2018.4399. Epub 2018 May 8. Int J Oncol. 2018. PMID: 29750424
-
Pre-clinical investigation of STAT3 pathway in bladder cancer: Paving the way for clinical translation.Biomed Pharmacother. 2021 Jan;133:111077. doi: 10.1016/j.biopha.2020.111077. Epub 2020 Dec 4. Biomed Pharmacother. 2021. PMID: 33378975 Review.
Cited by
-
Stat3 Inhibitors TTI-101 and SH5-07 Suppress Bladder Cancer Cell Survival in 3D Tumor Models.Cells. 2024 Aug 31;13(17):1463. doi: 10.3390/cells13171463. Cells. 2024. PMID: 39273033 Free PMC article.
-
Mechanisms and therapeutic prospect of the JAK-STAT signaling pathway in liver cancer.Mol Cell Biochem. 2025 Jan;480(1):1-17. doi: 10.1007/s11010-024-04983-5. Epub 2024 Mar 22. Mol Cell Biochem. 2025. PMID: 38519710 Review.
-
JAK2 Inhibition Impairs Proliferation and Sensitises Cervical Cancer Cells to Cisplatin-Induced Cell Death.Cancers (Basel). 2019 Dec 4;11(12):1934. doi: 10.3390/cancers11121934. Cancers (Basel). 2019. PMID: 31817106 Free PMC article.
-
Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics.Cancers (Basel). 2024 Jan 24;16(3):492. doi: 10.3390/cancers16030492. Cancers (Basel). 2024. PMID: 38339245 Free PMC article. Review.
-
Opposite Interplay Between the Canonical WNT/β-Catenin Pathway and PPAR Gamma: A Potential Therapeutic Target in Gliomas.Neurosci Bull. 2018 Jun;34(3):573-588. doi: 10.1007/s12264-018-0219-5. Epub 2018 Mar 26. Neurosci Bull. 2018. PMID: 29582250 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
